



ADVANCED INFORMATION

advanced biotech

LATEST NEWS FROM GNOSIS

Waiting Vitafoods...

Quatrefolic® in partnership with XYMOGEN® is short-listed for NutraIngredients Awards 2016!

The partnership between Gnosis and the US nutraceutical producer XYMOGEN® is proving innovative! XYMOGEN's XaQuil™XR, finished oral dose product containing Gnosis' Quatrefolic®, has been selected as a finalist of NutraIngredients Awards 2016 for the Finished Product of the Year - Medical Food category.

We are all cheering for XaQuil™XR & Quatrefolic®!

Silvia Pisoni
Marketing Manager

Know more about XYMOGEN®



Interview with the Founder and CEO, Brian Blackburn

XaQuil™XR, based on Gnosis' Quatrefolic®, has been selected as a finalist at the NutraIngredients Awards 2016 for the Finished Product of the Year - Medical Food category. What are the health benefit needs and improvements the product is designed to address?

Brian Blackburn: XaQuil™XR is an innovative medical food formulated as extended-release tablet, which constitutes an effective, safe, and well tolerated folate treatment for patients with major depressive disorder who have a partial response or no response to SSRIs (Selective Serotonin Reuptake Inhibitors).

We have developed XaQuil™XR because it fulfills the emergent clinical demand that have compelled psychiatrists to consider augmenting traditional antidepressants with the medical food L-methylfolate (5-MTHF).

We have based the XaQuil™XR formulation on Quatrefolic®, because it provides the natural and metabolically active form of folate, as glucosamine salt of 5-MTHF, and does not require further metabolism.

Folate deficiency is very common among depressed people, especially those who don't respond to antidepressants: major depressive disorder (MDD) currently ranks as the fourth leading disease burden worldwide and is expected to become the second global disease burden by the year 2020.

The statistics are impressive and we know that more than half of all patients treated with antidepressant monotherapy fails to experience a remission of their major depressive episode.

XaQuil™XR works through a natural process by supplying the distinct nutritional requirements needed by the brain to help the regulation of the neurotransmitters associated with mood.

Insights & tools



NutraIngredients Awards
2016 • FINALIST



In partnership with

PharmaceutiX
XaQuil™XR
(6S)-5-methyltetrahydrofolic acid, glucosamine salt)

by



XYMOGEN®

Vitafoods time!

The global nutraceutical event is growing each time and this year is no exception.

Vitafoods Europe

May 10th -12th
Palexpo, Geneva,
Switzerland
Booth #L31

Register for FREE
with reg code:
wbgnosis

The supplementation of folic acid is often suggested and used to raise folate levels, also in depressed people. Why should XaQuil™XR with Quatrefolic® be preferred over the use of folic acid supplementation?

Brian Blackburn: First of all I would like to emphasize that folic acid is the man-hand synthetic form of folate and it is biologically inactive as is. To become active it must be converted through a series of enzymatic conversions, one of which is sustained by the enzyme methyltetrahydrofolate reductase (MTHFR). As I mentioned before, patients partial- or non-responders may have limited capacity to convert folate and folic acid. These individuals express the enzyme MTHFR in polymorphic forms, which are less active and make ineffective folic acid supplementation, even if delivered at very high dosage.

Recent evidence has emphasized that up to 70% of patients with depression test positive for the polymorphism and cannot convert folic acid into 5-MTHF.

XaQuil™XR with Quatrefolic® is preferable to folic acid because it is not affected by this common impairment or other genetic impairments of folate metabolism that may be associated to psychiatric illness. Quatrefolic® essentially bypasses the enzymatic step that may be affected, crosses the "blood-brain barrier" and enters the central nervous system, helping to restore the optimal levels of brain folate.

Can you tell us the genesis and importance of the XYMOGEN® - Gnosis collaboration?

Brian Blackburn: Collaboration has been essential to this project. Our business relationship with Gnosis started several years ago which made it easy to partner, sharing knowledge and resources to realize a product that people can benefit from.

Our companies were able to agree and recognized the importance of the Quatrefolic® product to serving the folate deficiency market so in sharing our ideas we were able to create the XaQuil™XR formulation which leverages the intellectual property of the Quatrefolic® ingredient as well as the extended-release all natural coating technology.

What are the advantages of this innovative formulation and how can Xaquil™XR support people affected by depression?

Brian Blackburn: The use and benefits of folate supplementation in people suffering from folate deficiency and depression are well documented and recognized by the professional healthcare and nutritional community. This is an area of XYMOGEN® product and service focus.

The XaQuil™XR formulation is unique since it offers the bioavailable Quatrefolic® in a time release application that facilitates a more focused and optimized release of the folate 5-MTHF in the intestine, which should ultimately translate to a good experience for the consumer.

Stay always up-to-date on the latest news from Gnosis products: subscribe to [Quatrefolic® Online](#) and [vitaMK7®Pulse](#) newsletters!

Incoming Events 2016

June 21st - 23rd



SNIEC, Shanghai, China
Booth #E7D26

October 4th - 6th



Feria de Barcelona Spain
Booth #6K40

October 6th - 7th



Mandalay Bay Hotel
Las Vegas, USA
Booth #CC181